BioSpace News Archive

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the following investor conferences. William Blair 41 st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 6:40 a.m. Pacific Time / 9:40 a.m. Eastern Time

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.62 per share, payable on July 21, 2021 to shareholders of record of Quest Diagnostics common stock on July 7, 2021.

Introducing BEAST™ Injectable, BEAST PLUS™, and BEAST™ Osteobiologic Sponge for bone grafting applications in the foot and ankle.

Leucadia Pharmaceuticals, a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc., today announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.

With the onset of the pandemic and a new lens on the critical importance of clinical trial data oversight, CRAB decided to expand its services for Data Monitoring Committees.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS.

The new business is uniquely positioned to continue delivering research solutions for COVID-19 and beyond with community presence, data capabilities and health care expertise

Initial analysis of 400 patients from CIRCULATE-Japan study showcases Signatera’s market-leading performance with over 95% pre-surgical detection and 92% relapse sensitivity